<div id="readability-page-1"><p><span>Chemours (NYSE:CC - Get Free Report)</span> had its target price decreased by analysts at JPMorgan Chase &amp; Co.  from $15.00 to $13.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a &#34;neutral&#34; rating on the specialty chemicals company's stock. JPMorgan Chase &amp; Co.'s target price indicates a potential upside of 0.38% from the stock's previous close.</p><ul><li>3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors</li></ul><p>A number of other equities research analysts have also recently commented on CC. Mizuho dropped their price objective on shares of Chemours from $19.00 to $18.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, October 16th. Royal Bank Of Canada cut their price objective on shares of Chemours from $19.00 to $17.00 and set an &#34;outperform&#34; rating for the company in a report on Monday, November 10th. Zacks Research cut Chemours from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Friday, October 17th. Weiss Ratings  restated a &#34;sell (d)&#34; rating on shares of Chemours in a research note on Wednesday, October 8th. Finally, UBS Group dropped their price objective on Chemours from $21.00 to $18.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating, four have assigned  a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company  has an average rating of &#34;Hold&#34; and a consensus target price of $17.00.</p><p><b>View Our Latest Stock Report on Chemours</b></p><h2>Chemours Stock Performance</h2><ul><li>Nuclear Stocks Are Melting Down—Should Investors Panic?</li></ul><p>Shares of Chemours stock traded up $0.18 during trading on Wednesday, hitting $12.95. 297,335 shares of the company's stock were exchanged, compared to its average volume of 3,387,335. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -5.83 and a beta of 1.59. The business has a 50-day simple moving average of $13.38 and a 200-day simple moving average of $13.26. Chemours has a 52-week low of $9.13 and a 52-week high of $22.26. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. </p><p>Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.04). The company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.50 billion. Chemours had a negative net margin of 5.70% and a positive return on equity of 35.27%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.40 EPS.  On average, research analysts forecast that  Chemours will post 2.03 EPS for the current year. </p><h2>Institutional Investors Weigh In On Chemours</h2><ul><li>3 Alternative Energy ETFs That Are Crushing the Market This Year</li></ul><p>A number of large investors have recently modified their holdings of CC. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in  Chemours during the first quarter worth about $174,000.  LPL Financial LLC grew its position in shares of  Chemours by 77.8% in the first quarter. LPL Financial LLC now owns 122,317 shares of the specialty chemicals company's stock valued at $1,655,000 after purchasing an additional 53,520 shares in the last quarter.  XTX Topco Ltd acquired a new stake in shares of  Chemours in the first quarter valued at approximately $285,000.  Natixis Advisors LLC purchased a new position in  Chemours during the first quarter worth approximately $341,000.  Finally, Jefferies Financial Group Inc. purchased a new position in  Chemours during the first quarter worth approximately $303,000. Hedge funds and other institutional investors own  76.26% of the company's stock. </p><h2>Chemours Company Profile</h2> (Get Free Report)<p>The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Chemours</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>The AI Boom Is Powering an Unexpected Stock Surge—And These 3 Companies Are Winning Big</li><li>What is a Death Cross in Stocks?</li><li>The Bulls Are Back—Why Qualcomm Stock Is Gaining Strength Again</li><li>When to Sell a Stock for Profit or Loss</li><li>Netflix Goes All In: The $70B Play to End the Streaming Wars</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Chemours Right Now?</h2><p>Before you consider Chemours, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.</p><p>While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>JPMorgan Chase & Co. lowered Chemours' stock price target from $15.00 to $13.00, maintaining a "neutral" rating. Other analysts also adjusted their targets, with Mizuho and Royal Bank of Canada setting "outperform" ratings, while Zacks Research downgraded to "strong sell." The consensus target price is $17.00, with mixed ratings from analysts.</p>

JPMorgan Chase & Co. Has Lowered Expectations for Chemours (NYSE:CC) Stock Price